Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 2/20 | 0.40 |
| ▸ | NPY2R | P49146 | 2/20 | 0.40 |
| ▸ | NPY4R | P50391 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17722897 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY1R | |
| SCHEMBL24164488 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY1R | |
| SCHEMBL17815434 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY1R | |
| SCHEMBL19705471 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY1R | |
| SCHEMBL22910731 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY1R | |
| SCHEMBL19647265 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY1R | |
| SCHEMBL22643617 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY1R | |
| SCHEMBL21008370 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY1R | |
| SCHEMBL25094717 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY1R | |
| SCHEMBL19708927 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4233909-A2 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3804765-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2020236797-A1 | VARIANT CD58 DOMAINS AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236792-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| EP-3212668-B1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | SIRT2 4097/4885SIRT1 4465/4885SIRT3 4488/4885 |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | SIRT2 4097/4885SIRT1 4465/4885SIRT3 4488/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | SIRT2 4689/4885SIRT1 4857/4885SIRT3 4865/4885 |
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | SIRT2 4689/4885SIRT1 4857/4885SIRT3 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.